Treatment response, symptom remission, and wellness in obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 74, Issue 7, 2013, Pages 685-690

  Farris, Samantha G ^a,c   McLean, Carmen P ^a   Van Meter, Page E ^b   Simpson, Helen Blair ^b   Foa, Edna B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; CONTROLLED STUDY; CONVERGENT VALIDITY; DIAGNOSTIC TEST ACCURACY STUDY; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATIONAL INTERVIEWING; OBSESSIVE COMPULSIVE DISORDER; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; SOCIAL ADJUSTMENT SCALE SELF REPORT; SYMPTOMATOLOGY; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADAPTATION, PSYCHOLOGICAL; ADULT; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84880975672     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.12m07789     Document Type: Article

References (37)

1. Huppert JD, Simpson HB, Nissenson KJ, et al. Quality of life and functional impairment in obsessive compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depress Anxiety. 2009;26(1):39-45.
2. Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53-63.
3. Gladis MM, Gosch EA, Dishuk NM, et al. Quality of life: expanding the scope of clinical significance. J Consult Clin Psychol. 1999;67(3):320-331.
4. Kazdin A. Almost clinically significant (P< .10): current measures may only approach clinical significance. Clin Psychol Sci Pract. 200-1;8(4):455-462.
5. Moritz S, Rufer M, Fricke S, et al. Quality of life in obsessive compulsive disorder before and after treatment. Compr Psychiatry. 2005;46(6):453-459.
6. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67(9):1428-1434.
7. Davidoff J, Christensen S, Khalii DN, et al. Quality of life in panic disorder: looking beyond symptom remission. Qual Life Res. 2012;21(6) :945-959.
8. Zimmerman M, Martinez J, Attiullah N, et al. Further evidence that the cutoff to define remission on the 17-item Hamilton Depression Rating Scale should be lowered. Depress Anxiety. 2012;29(2): 159-165.
9. Goodman WK, Price LH, Rasmussen SA, et al. The Yale Brown Obsessive Compulsive Scale, 2: validity. Arch Gen Psychiatry. 1989;46(11):1012-1016.
10. Guy W ECDEU Assessment Manualfor Psychopharmacology US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:2-18-222.
11. Simpson HB, Huppert JD, Petkova E, et al. Response versus remission in obsessive compulsive disorder. J Clin Psychiatry. 2006;67(2):269-276.
12. Lewin AB, De Nadai AS, Park J, et al. Refining clinical judgment of treatment outcome in obsessive compulsive disorder. Psychiatry Res. 2011;185(3):394-401.
13. Storch FA, Lewin AB, De Nadai AS, et al. Defining treatment response and remission in obsessive compulsive disorder: a signal detection analysis of the Childrens Yale Brown Obsessive Compulsive Scale. J Am Acad Child Adolesc Psychiatry. 20-10;49(7):708-717.
14. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive compulsive disorder: a signal detection analysis of the Yale Brown Obsessive Compulsive Scale. J Clin Psychiatry. 2005;66(12):1549-1557.
15. Simpson HB, Franklin ME, Cheng J, et al. Standard criteria for relapse are needed in obsessive compulsive disorder. Depress Anxiety. 2005;21(1):1-8.
16. Bystritsky A, Saxena S, Maidment K, et al. Quality of life changes among patients with obsessive compulsive disorder in a partial hospitalization program. Psychiatr Serv. 1999;50(3):412-414.
17. Koran LM. Quality of life in obsessive compulsive disorder. Psychiatr Clin North Am. 2000;23(3):509-517.
18. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive compulsive disorder. Am J Psychiatry. 2005;162(1):151-161.
19. Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive behavioral therapy for augmenting pharmacotherapy in obsessive compulsive disorder. Am J Psychiatry. 2008;165(5):621-630.
20. Simpson HB, Maher MJ, Wang Y, et al. Patient adherence predicts outcome from cognitive behavioral therapy in obsessive compulsive disorder. J Consult Clin Psychol. 2011;79(2):247-252.
21. Simpson HB, Foa EB. A randomized controlled trial of cognitive behavioral therapy versus risperidone for augmenting serotonin reuptake inhibitors in obsessive compulsive disorder. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Neuropsychopharmacology. 2012;38:5330-S331.
22. American Psychiatric Association. Diagnostic and Statistical Manual Of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
23. Goodman WK, Price LH. Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15(4):861-869.
24. Goodman WK, Price LH, Rasmussen SA, et al. The Yale Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
25. Woody SR, Steketee G, Chambless DL. Reliability and validity of the Yale Brown Obsessive Compulsive Scale. Behav Res Ther. 1995;33(5):597-605.
26. Bergeron R, Ravindran AM Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive compulsive disorder: results of a double blind, 6-month treatment study. J Clin Psychopharmacol. 2002;22(2):148-154.
27. Hollander E, Koran LM, Goodman WK, et al. A double blind, placebo controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive compulsive disorder. J Clin Psychiatry. 2003;64(6):640-647.
28. Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatment resistant obsessive compulsive disorder: a preliminary, single blind, prospective study. CNS Drugs. 2009;23(12):1047-1055.
29. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
30. Rapaport MH, Clary C, Fayyad R, et al. Quality of life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162(6): 1171-1178.
31. Weissman MM, Bothwell S. Assessment of social adjustment by patient self report. Arch Gen Psychiatry. 1976;33(9):11-11-1115.
32. Weissman MM, Prusoff BA, Thompson WD, et al. Social adjustment by self report in a community sample and in psychiatric outpatients. J Nerv MentDis. 1978;166(5):317-326.
33. Fischer J, Corcoran K. Measures for Clinical Practice. Vol.2. New York, NY: Free Press; 1994:580.
34. Jacobson NS, Roberts U, Berns SB, et al. Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol. 1999;67(3):300-307.
35. Chmura Kraemer H, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med. 2002;21(14):2109-2129.
36. Eddy KT, Dutra U, Bradley R, et al. A multidimensional meta analysis of psychotherapy and pharmacotherapy for obsessive compulsive disorder. Clin Psychol Rev. 2004;24(8):1011-1030.
37. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360-363.